Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumour cell and the tumour microenvironment, announced the publication of study results describing the preclinical profile of its phase 1 anti-cancer product candidate, altiratinib, a balanced, spectrum-selective inhibitor of MET, TIE2, and VEGFR2 kinases.